TY - JOUR
T1 - Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy
T2 - An exploratory study
AU - Molinari, Chiara
AU - Ballardini, Michela
AU - Teodorani, Nazario
AU - Giannini, Massimo
AU - Zoli, Wainer
AU - Emiliani, Ermanno
AU - Lucci, Enrico
AU - Passardi, Alessandro
AU - Rosetti, Paola
AU - Saragoni, Luca
AU - Guidoboni, Massimo
AU - Amadori, Dino
AU - Calistri, Daniele
PY - 2011/11/18
Y1 - 2011/11/18
N2 - Background: Neoadjuvant chemoradiotherapy is the treatment of choice in advanced rectal cancer, even though there are many patients who will not benefit from it. There are still no effective methods for predicting which patients will respond or not. The present study aimed to define the genomic profile of rectal tumors and to identify alterations that are predictive of response in order to optimize therapeutic strategies.Methods: Forty-eight candidates for neoadjuvant chemoradiotherapy were recruited and their pretherapy biopsies analyzed by array Comparative Genomic Hybridization (aCGH). Pathologic response was evaluated by tumor regression grade.Results: Both Hidden Markov Model and Smoothing approaches identified similar alterations, with a prevalence of DNA gains. Non responsive patients had a different alteration profile from responsive ones, with a higher number of genome changes mainly located on 2q21, 3q29, 7p22-21, 7q21, 7q36, 8q23-24, 10p14-13, 13q12, 13q31-34, 16p13, 17p13-12 and 18q23 chromosomal regions.Conclusions: This exploratory study suggests that an in depth characterization of chromosomal alterations by aCGH would provide useful predictive information on response to neoadjuvant chemoradiotherapy and could help to optimize therapy in rectal cancer patients.The data discussed in this study are available on the NCBI Gene Expression Omnibus [GEO: GSE25885].
AB - Background: Neoadjuvant chemoradiotherapy is the treatment of choice in advanced rectal cancer, even though there are many patients who will not benefit from it. There are still no effective methods for predicting which patients will respond or not. The present study aimed to define the genomic profile of rectal tumors and to identify alterations that are predictive of response in order to optimize therapeutic strategies.Methods: Forty-eight candidates for neoadjuvant chemoradiotherapy were recruited and their pretherapy biopsies analyzed by array Comparative Genomic Hybridization (aCGH). Pathologic response was evaluated by tumor regression grade.Results: Both Hidden Markov Model and Smoothing approaches identified similar alterations, with a prevalence of DNA gains. Non responsive patients had a different alteration profile from responsive ones, with a higher number of genome changes mainly located on 2q21, 3q29, 7p22-21, 7q21, 7q36, 8q23-24, 10p14-13, 13q12, 13q31-34, 16p13, 17p13-12 and 18q23 chromosomal regions.Conclusions: This exploratory study suggests that an in depth characterization of chromosomal alterations by aCGH would provide useful predictive information on response to neoadjuvant chemoradiotherapy and could help to optimize therapy in rectal cancer patients.The data discussed in this study are available on the NCBI Gene Expression Omnibus [GEO: GSE25885].
KW - Arraycgh
KW - Genomic alterations
KW - Neoadjuvant chemoradiotherapy
KW - Rectal cancer
UR - http://www.scopus.com/inward/record.url?scp=81255128107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81255128107&partnerID=8YFLogxK
U2 - 10.1186/1748-717X-6-161
DO - 10.1186/1748-717X-6-161
M3 - Article
C2 - 22099067
AN - SCOPUS:81255128107
VL - 6
JO - Radiation Oncology
JF - Radiation Oncology
SN - 1748-717X
IS - 1
M1 - 161
ER -